C. R. Bard, Inc. (NYSE: BCR) today reported 2012 fourth quarter financial results. Fourth quarter 2012 net sales were $762.6 million, an increase of 1 percent over the prior-year period on an as-reported basis. Excluding the impact of foreign exchange, fourth quarter 2012 net sales increased 2 percent over the prior-year period.

For the fourth quarter 2012, net sales in the U.S. were $498.1 million and net sales outside the U.S. were $264.5 million, a decrease of 1 percent and an increase of 6 percent, respectively, over the prior-year period. Excluding the impact of foreign exchange, fourth quarter 2012 net sales outside the U.S. increased 8 percent over the prior-year period.

Net sales for the full year 2012 were $2,958.1 million, an increase of 2 percent over the prior-year period. Excluding the impact of foreign exchange, full year 2012 net sales increased 3 percent over the prior-year period.

For the fourth quarter 2012, net income was $128.2 million and diluted earnings per share available to common shareholders were $1.52, an increase of 13 percent and 17 percent, respectively, as compared to fourth quarter 2011 results. Adjusting for items that affect comparability between periods as detailed in the tables below, fourth quarter 2012 net income was $143.9 million and diluted earnings per share available to common shareholders were $1.70, a decrease of 3 percent and unchanged, respectively, as compared to fourth quarter 2011 results.

For the full year 2012, net income was $530.1 million and diluted earnings per share available to common shareholders were $6.16, an increase of 62 percent and 67 percent, respectively, as compared to full year 2011 results. Adjusting for items that affect comparability between periods, full year 2012 net income was $565.3 million and diluted earnings per share available to common shareholders were $6.57, a decrease of 1 percent and an increase of 3 percent, respectively, as compared to full year 2011 results.

Timothy M. Ring, chairman and chief executive officer, commented, "While the near term environment remains challenging, especially in our developed markets, we are executing a strategy to return to faster growth through investments in emerging markets and new product categories. We believe the size of the opportunities in front of us and the capabilities of our organization have never been better, and we are investing to aggressively pursue these opportunities."

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as "anticipate", "estimate", "expect", "project", "intend", "forecast", "plan", "believe", and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our September 30, 2012 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.

 
C. R. Bard, Inc.
Consolidated Statements of Income
(dollars and shares in thousands except per share amounts, unaudited)
 
        Quarter Ended       Twelve Months Ended
December 31, December 31,

2012

      

2011

2012

      

2011

 
Net sales $ 762,600 $ 751,900 $ 2,958,100 $ 2,896,400
Costs and expenses
Cost of goods sold 287,600 282,100 1,125,300 1,097,300
Marketing, selling and administrative expense 213,000 214,200 817,300 794,600
Research and development expense 52,700 43,600 203,200 185,400
Interest expense 10,700 9,300 39,600 36,400
Other (income) expense, net   21,300   60,700   40,300   271,900
 
Total costs and expenses   585,300   609,900   2,225,700   2,385,600
Income from operations before income taxes   177,300   142,000   732,400   510,800
 
Income tax provision   49,100   28,200   202,300   182,800
 
Net income $ 128,200 $ 113,800 $ 530,100 $ 328,000
 
Basic earnings per share available to common shareholders $ 1.54 $ 1.31 $ 6.24 $ 3.75
 
Diluted earnings per share available to common shareholders $ 1.52 $ 1.30 $ 6.16 $ 3.69
 
Wt. avg. common shares outstanding - basic 82,000 85,200 83,300 85,800
 
 
Wt. avg. common and common equivalent shares outstanding - diluted 83,100 86,000 84,400 87,300
 
 
Product Group Summary of Net Sales
(dollars in thousands, unaudited)
 
 
          Quarter Ended December 31,     Twelve Months Ended December 31,
                  Constant                   Constant
2012       2011         Change       Currency 2012       2011         Change       Currency
Vascular $ 212,000 $ 220,700 -4 % -2 % $ 845,000 $ 842,400 - 3 %
Urology 195,800 190,400 3 % 3 % 757,800 734,800 3 % 4 %
Oncology 210,500 201,400 5 % 5 % 812,400 779,500 4 % 5 %
Surgical Specialties 121,300 116,600 4 % 4 % 455,100 450,000 1 % 2 %
Other   23,000   22,800   1 % -   87,800   89,700   -2 % -2 %
 
Net sales $ 762,600 $ 751,900   1 % $ 2,958,100 $ 2,896,400   2 %
 
Foreign exchange impact   (4,300 )     (34,100 )
Constant Currency $ 762,600 $ 747,600   2 % $ 2,958,100 $ 2,862,300   3 %
 
 
Reconciliation of Earnings
(dollars in millions except per share amounts, unaudited)
 
 
        Quarter Ended December 31, 2012
                                  Diluted
Earnings
Marketing, per Share
Cost of Selling and Research & Other Available
Goods Administrative Development (Income) Income Net to Common
Sold Expense Expense Expense, Net Taxes Income Shareholders (1)
 
GAAP Basis $ 287.6 $ 213.0 $ 52.7 $ 21.3 $ 49.1 $ 128.2 $ 1.52
Items that affect comparability of
results between periods:
Acquisition related items (0.1 ) (0.8 ) (1.9 ) (0.3 ) 0.3 2.8
Restructuring   -     -     -     (19.0 )   6.1     12.9    
Total (0.1 ) (0.8 ) (1.9 ) (19.3 ) 6.4 15.7 0.19
             
Adjusted Basis $ 287.5   $ 212.2   $ 50.8   $ 2.0   $ 55.5   $ 143.9   $ 1.70
 
 
Quarter Ended December 31, 2011
Diluted
Earnings
Marketing, per Share
Cost of Selling and Research & Other Available
Goods Administrative Development (Income) Income Net to Common
Sold Expense Expense Expense, Net Taxes Income Shareholders
 
GAAP Basis $ 282.1 $ 214.2 $ 43.6 $ 60.7 $ 28.2 $ 113.8 $ 1.30

Items that affect comparability of   

 

results between periods:

Acquisition related items - (3.8 ) - (4.1 ) 1.0 6.9
Legal settlement - - - (51.0 ) 10.2 40.8
Impairment of bonds - - - (4.5 ) - 4.5
Restructuring - - - 1.1 (0.2 ) (0.9 )
Tax items   -     -     -     -     16.5     (16.5 )  
Total - (3.8 ) - (58.5 ) 27.5 34.8 0.40
             
Adjusted Basis $ 282.1   $ 210.4   $ 43.6   $ 2.2   $ 55.7   $ 148.6   $ 1.70
 
 
Twelve Months Ended December 31, 2012
Diluted
Earnings
Marketing, per Share
Cost of Selling and Research & Other Available
Goods Administrative Development (Income) Income Net to Common
Sold Expense Expense Expense, Net Taxes Income Shareholders
 
GAAP Basis $ 1,125.3 $ 817.3 $ 203.2 $ 40.3 $ 202.3 $ 530.1 $ 6.16
Items that affect comparability of
results between periods:
Acquisition related items (0.2 ) (2.0 ) (5.1 ) (2.1 ) 0.9 8.5
Asset impairments - - - (22.2 ) 8.4 13.8
Restructuring - - - (17.4 ) 5.6 11.8
Tax item   -     -     -     -     (1.1 )   1.1    
Total (0.2 ) (2.0 ) (5.1 ) (41.7 ) 13.8 35.2 0.41
             
Adjusted Basis $ 1,125.1   $ 815.3   $ 198.1   $ (1.4 ) $ 216.1   $ 565.3   $ 6.57
 
 
Twelve Months Ended December 31, 2011
Diluted
Earnings
Marketing, per Share
Cost of Selling and Research & Other Available
Goods Administrative Development (Income) Income Net to Common
Sold Expense Expense Expense, Net Taxes Income Shareholders
 
GAAP Basis $ 1,097.3 $ 794.6 $ 185.4 $ 271.9 $ 182.8 $ 328.0 $ 3.69
Items that affect comparability of
results between periods:
Acquisition related items 0.4 (6.8 ) (3.5 ) (4.4 ) 2.6 11.7
Legal settlements and commitments - - - (246.5 ) 16.2 230.3
Impairment of bonds - - - (11.5 ) - 11.5
Restructuring - - - (7.8 ) 2.8 5.0
Tax items   -     -     -     -     17.6     (17.6 )  
Total 0.4 (6.8 ) (3.5 ) (270.2 ) 39.2 240.9 2.71
             
Adjusted Basis $ 1,097.7   $ 787.8   $ 181.9   $ 1.7   $ 222.0   $ 568.9   $ 6.40
 
(1) Total per share amounts do not add due to rounding.
 

Notes to Reconciliation of Earnings

  • For the fourth quarter 2012, the following items affected the comparability of results between periods: (i) charges of $3.1 million pre-tax for acquisition related items including purchased research and development, transaction costs, purchase accounting adjustments and integration costs; and (ii) net charges of $19.0 million pre-tax for restructuring costs. The net effect of these items decreased net income by $15.7 million, or $0.19 diluted earnings per share available to common shareholders.
  • For the fourth quarter 2011, the following items affected the comparability of results between periods: (i) charges of $7.9 million pre-tax for acquisition related items including transaction costs, purchase accounting adjustments and integration costs; (ii) a charge of $51.0 million pre-tax related to a preliminary legal settlement; (iii) a charge of $4.5 million pre-tax for the impairment of Greek bonds; (iv) a net reversal of $1.1 million pre-tax for restructuring costs; and (v) a decrease of $16.5 million in the income tax provision associated with audit settlements related to the completion of IRS examinations for the tax years from 2005 through 2007 and certain examinations in a foreign jurisdiction. The net effect of these items decreased net income by $34.8 million, or $0.40 diluted earnings per share available to common shareholders.
  • For the twelve months ended December 31, 2012, the following items affected the comparability of results between periods: (i) charges of $9.4 million pre-tax for acquisition related items including purchased research and development, transaction costs, purchase accounting adjustments and integration costs; (ii) charges of $22.2 million pre-tax related to asset impairments; (iii) net charges of $17.4 million pre-tax for restructuring costs; and (iv) an increase of $1.1 million in the income tax provision due to the write-down of a tax receivable in a foreign jurisdiction. The net effect of these items decreased net income by $35.2 million, or $0.41 diluted earnings per share available to common shareholders.
  • For the twelve months ended December 31, 2011, the following items affected the comparability of results between periods: (i) charges of $14.3 million pre-tax for acquisition related items including purchased research and development, transaction costs, purchase accounting adjustments and integration costs; (ii) charges of $246.5 million pre-tax related to legal settlements and commitments; (iii) charges of $11.5 million pre-tax for the impairment of Greek bonds; (iv) net charges of $7.8 million pre-tax for restructuring costs; and (v) a decrease of $17.6 million in the income tax provision associated with audit settlements related to the completion of IRS examinations for the tax years from 2005 through 2007 and certain examinations in other jurisdictions. The net effect of these items decreased net income by $240.9 million, or $2.71 diluted earnings per share available to common shareholders.

This press release contains financial measures that are not calculated in accordance with United States generally accepted accounting principles (GAAP). These non-GAAP measures are reconciled to their most directly comparable GAAP measures in the above tables.

This press release includes net sales excluding the impact of foreign exchange. The company analyzes net sales on a constant currency basis to better measure the comparability of results between periods. Because changes in foreign currency exchange rates have a non-operating impact on net sales, the company believes that evaluating growth in net sales on a constant currency basis provides an additional and meaningful assessment of net sales to both management and the company's investors.

In addition, this press release includes the following non-GAAP measures: (1) cost of goods sold excluding charges for acquisition related items; (2) marketing, selling and administrative expense excluding charges for acquisition related items; (3) research and development expense excluding charges for acquisition related items; (4) other (income) expense, net, excluding charges for acquisition related items, asset impairments, legal settlements and commitments, restructuring and impairment of bonds; (5) income tax provision excluding an increase due to the write-down of a tax receivable in a foreign jurisdiction, a decrease due to audit settlements, and the tax effect of the items set forth in (1) through (4) above; (6) net income excluding the items set forth in (1) through (5) above; and (7) diluted earnings per share available to common shareholders excluding the items set forth in (1) through (5) above.

The company excluded the items described above because they may cause certain statements of operations categories not to be indicative of ongoing operating results, and therefore affect the comparability of results between periods. The company therefore believes that these non-GAAP measures provide an additional and meaningful assessment of the company's ongoing operating performance. Because the company has historically reported these non-GAAP results to the investment community, management also believes that the inclusion of these non-GAAP measures provides consistency in its financial reporting and facilitates investors' understanding of the company's historic operating trends by providing an additional basis for comparisons to prior periods. Management uses these non-GAAP measures: (1) to establish financial and operational goals; (2) to monitor the company's actual performance in relation to its business plan and operating budgets; (3) to evaluate the company's core operating performance and understand key trends within the business; and (4) as part of several components it considers in determining incentive compensation.

Management recognizes that the use of these non-GAAP measures has limitations, including the fact that they may not be comparable with similar non-GAAP measures used by other companies and that management must exercise judgment in determining which types of charges or other items should be excluded from the non-GAAP information. Management compensates for these limitations by providing full disclosure of each non-GAAP measure and a reconciliation to the most directly comparable GAAP measure. All non-GAAP measures are intended to supplement the applicable GAAP disclosures and should not be considered in isolation from, or as a replacement for, financial information prepared in accordance with GAAP. For a reconciliation of these non-GAAP measures to the most comparable GAAP measures, please see the above tables.

 

Notes to Earnings per Share

(dollars and shares in thousands, except per share amounts, unaudited)

 
        Quarter Ended       Twelve Months Ended
December 31, December 31,
2012       2011 2012       2011
Earnings per Share Numerator: GAAP Basis - basic and diluted
Net income $ 128,200 $ 113,800 $ 530,100 $ 328,000
Less: Income allocated to participating securities (1)   2,200   2,000   10,000   6,100
Net income available to common shareholders $ 126,000 $ 111,800 $ 520,100 $ 321,900
 
 
Earnings per Share Numerator: Adjusted Basis - diluted
Net income $ 143,900 $ 148,600 $ 565,300 $ 568,900
Less: Income allocated to participating securities (1)   2,500   2,700   10,600   10,100
Net income available to common shareholders $ 141,400 $ 145,900 $ 554,700 $ 558,800
 
Earnings per Share Denominator:
Wt. avg. common shares outstanding - basic 82,000 85,200 83,300 85,800
 
Wt. avg. common and common equivalent shares outstanding - diluted 83,100 86,000 84,400 87,300
 
Earnings per Share: GAAP Basis
Basic earnings per share available to common shareholders $ 1.54 $ 1.31 $ 6.24 $ 3.75
 
Diluted earnings per share available to common shareholders $ 1.52 $ 1.30 $ 6.16 $ 3.69
 
Earnings per Share: Adjusted Basis
Diluted earnings per share available to common shareholders $ 1.70 $ 1.70 $ 6.57 $ 6.40
 
(1) Basic and diluted earnings per share available to common shareholders is calculated using a numerator, which represents the total of net income attributable to common shareholders less income allocated to participating securities.
 

C. R. Bard, Inc.
Investor Relations:
Todd W. Garner, 908-277-8065
Vice President, Investor Relations
or
Media Relations:
Scott T. Lowry, 908-277-8365
Vice President and Treasurer